(Reuters) - On Thursday, the biopharmaceutical firm's shares priced at $18, compared with a forecast range of $20 to $21.
The forecast range was initially $24 to $26 before being cut earlier on Thursday, according to an amended filing with the U.S. Securities and Exchange Commission.
Read more at Reuters.com Hot Stocks News
The forecast range was initially $24 to $26 before being cut earlier on Thursday, according to an amended filing with the U.S. Securities and Exchange Commission.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment